Impact of the COVID-19 Pandemic on Global TAVR Activity: The COVID-TAVI Study.

Publication date: Feb 12, 2024

The COVID-19 pandemic adversely affected health care systems. Patients in need of transcatheter aortic valve replacement (TAVR) are especially susceptible to treatment delays. This study sought to evaluate the impact of the COVID-19 pandemic on global TAVR activity. This international registry reported monthly TAVR case volume in participating institutions prior to and during the COVID-19 pandemic (January 2018 to December 2021). Hospital-level information on public vs private, urban vs rural, and TAVR volume was collected, as was country-level information on socioeconomic status, COVID-19 incidence, and governmental public health responses. We included 130 centers from 61 countries, including 65,980 TAVR procedures. The first and second pandemic waves were associated with a significant reduction of 15% (P < 0. 001) and 7% (P < 0. 001) in monthly TAVR case volume, respectively, compared with the prepandemic period. The third pandemic wave was not associated with reduced TAVR activity. A greater reduction in TAVR activity was observed in Africa (-52%; P = 0. 001), Central-South America (-33%; P < 0. 001), and Asia (-29%; P < 0. 001). Private hospitals (P = 0. 005), urban areas (P = 0. 011), low-volume centers (P = 0. 002), countries with lower development (P

Concepts Keywords
Hospitals aortic valve stenosis
Monthly coronavirus disease 2019
Pandemic valvular heart disease


Type Source Name
disease MESH COVID-19 Pandemic
disease VO monthly
disease VO volume
disease IDO country
disease MESH aortic valve stenosis
disease MESH valvular heart disease

Original Article

(Visited 1 times, 1 visits today)